Lexeo Therapeutics (LXEO) Restructuring Costs (2024 - 2026)

Lexeo Therapeutics has reported Restructuring Costs for 3 years, with the latest figure at $4.7 million in Q1 2026.

• Quarterly Restructuring Costs fell 62.52% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.1 million (down 10.78% YoY) and the FY2025 annual result came in at $37.0 million, up 48.06% from the prior year.
• Restructuring Costs fell to $4.7 million in Q1 2026 per LXEO's latest filing, from $9.3 million in the prior quarter.
• Over five years, Restructuring Costs peaked at $12.6 million in Q1 2025 and troughed at $2.9 million in Q3 2025.
• A 3-year average of $7.4 million and a median of $4.9 million in 2024 frame the typical range for Restructuring Costs.
• The sharpest annual moves came in 2025 and 2026: Restructuring Costs jumped 209.04% in 2025, then plunged 62.52% in 2026.
• Over 3 years, Restructuring Costs stood at $11.8 million in 2024, then decreased by 21.02% to $9.3 million in 2025, then sank by 49.47% to $4.7 million in 2026.
• According to Business Quant data, Restructuring Costs over the past three periods registered $4.7 million, $9.3 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.